Ballentine Partners’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $295K | Buy |
+3,377
| New | +$295K | ﹤0.01% | 697 |
|
|
2025
Q1 | – | Sell |
-2,762
| Closed | -$215K | – | 936 |
|
|
2024
Q4 | $215K | Buy |
+2,762
| New | +$215K | ﹤0.01% | 757 |
|
|
2024
Q3 | – | Sell |
-2,256
| Closed | -$256K | – | 856 |
|
|
2024
Q2 | $256K | Sell |
2,256
-261
| -10% | -$29.6K | ﹤0.01% | 612 |
|
|
2024
Q1 | $349K | Buy |
2,517
+266
| +12% | +$36.9K | 0.01% | 491 |
|
|
2023
Q4 | $279K | Sell |
2,251
-902
| -29% | -$112K | 0.01% | 522 |
|
|
2023
Q3 | $294K | Buy |
3,153
+694
| +28% | +$64.8K | 0.01% | 449 |
|
|
2023
Q2 | $316K | Sell |
2,459
-766
| -24% | -$98.4K | 0.01% | 434 |
|
|
2023
Q1 | $375K | Buy |
3,225
+940
| +41% | +$109K | 0.01% | 368 |
|
|
2022
Q4 | $259K | Buy |
+2,285
| New | +$259K | 0.01% | 415 |
|